Hartford Financial Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Hartford Financial Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.48K	Sell	5 -4	-44%	-$1.77K	﹤0.01%	327
2026 Q1	$4.02K	Sell	9 -3	-25%	-$1.4K	﹤0.01%	307
2025 Q4	$5.44K	Hold	12	–	–	﹤0.01%	289
2025 Q3	$4.7K	Buy	12 +2	+20%	+$836	﹤0.01%	295
2025 Q2	$4.45K	Hold	10	–	–	﹤0.01%	296
2025 Q1	$4.85K	Hold	10	–	–	﹤0.01%	305
2024 Q4	$4.03K	Hold	10	–	–	﹤0.01%	324
2024 Q3	$4.65K	Hold	10	–	–	﹤0.01%	326
2024 Q2	$4.69K	Hold	10	–	–	﹤0.01%	328
2024 Q1	$4.18K	Hold	10	–	–	﹤0.01%	336
2023 Q4	$4.07K	Sell	10 -9	-47%	-$3.33K	﹤0.01%	340
2023 Q3	$6.61K	Hold	19	–	–	﹤0.01%	323
2023 Q2	$6.69K	Hold	19	–	–	﹤0.01%	304
2023 Q1	$5.99K	Hold	19	–	–	﹤0.01%	304
2022 Q4	$5.49K	Hold	19	–	–	﹤0.01%	306
2022 Q3	$6K	Sell	19 -5	-21%	-$1.44K	﹤0.01%	307
2022 Q2	$7K	Hold	24	–	–	﹤0.01%	302
2022 Q1	$6K	Buy	+24	New	+$5.7K	﹤0.01%	326
2018 Q3	–	Sell	-670	Closed	-$114K	–	424
2018 Q2	$114K	Hold	670	–	–	0.04%	186
2018 Q1	$109K	Hold	670	–	–	0.06%	152
2017 Q4	$100K	Hold	670	–	–	0.05%	158
2017 Q3	$101K	Hold	670	–	–	0.05%	158
2017 Q2	$86K	Hold	670	–	–	0.04%	170
2017 Q1	$73K	Buy	+670	New	+$59K	0.04%	165

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Hartford Financial Management's VRTX Position: Q2 2026 in Review

Hartford Financial Management reduced its Vertex Pharmaceuticals (VRTX) stake by 44% in Q2 2026, selling an estimated $1.77K and leaving 5 shares worth $2.48K. The position accounts for ﹤0.01% of the portfolio, ranked #327.

Hartford Financial Management first reported a position in VRTX in Q1 2017 and has held it in 24 quarters since. The position peaked at $114K in Q2 2018. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Hartford Financial Management held 5 shares of Vertex Pharmaceuticals worth $2.48K as of Q2 2026.
Hartford Financial Management sold 4 Vertex Pharmaceuticals shares in Q2 2026, an estimated $1.77K.
Vertex Pharmaceuticals made up ﹤0.01% of Hartford Financial Management's portfolio in Q2 2026, its #327 holding.
Hartford Financial Management first reported a position in Vertex Pharmaceuticals in Q1 2017 and has held it in 24 quarters since.
Hartford Financial Management's Vertex Pharmaceuticals position peaked at $114K in Q2 2018.
1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Hartford Financial Management's 13F filing for Q2 2026, filed 24 Jul 2026.